Bio-Rad Laboratories (NYSE:BIO) this week said it acquired Celsee for an undisclosed amount. Celsee develops instruments and consumables for the isolation, detection and analysis of single cells. The company’s Genesis System allows scientists to isolate, analyze and interpret cellular behavior and collect cell-based information for improved results in single-cell cytometry, single-cell transcriptomics, single-cell multiomics, rare-cell enrichment […]
Bio-Rad launches COVID-19 assay
Bio-Rad Laboratories (NYSE:BIO) today said it is launching is blood-based immunoassay kit to identify COVID-19 antibodies. The assay is currently undergoing clinical evaluation in several hospitals, but 700 samples of data have shown specificity above 99%. After being infected with SARS-CoV-2, viral antigens stimulate the immune system to produce antibodies and fight the virus. Bio-Rad suggests […]
Bio-Rad Laboratories appoints new head of clinical diagnostics group
Research and clinical diagnostics company Bio-Rad Laboratories (NYSE:BIO) announced that it has appointed Dara Grantham Wright as its executive VP and president of the clinical diagnostics group in a move made effective on Jan. 1. Grantham Wright is taking over for John Hertia, who retired from the position on Dec. 31, 2019. Her responsibilities include providing […]
Bio-Rad beats expectations on Q2 results
Bio-Rad Laboratories (NYSE:BIO) posted second-quarter earnings this evening that beat the consensus forecast on Wall Street. The Hercules, Calif.–based life science research and clinical diagnostics manufacturer reported profits of $598.8 million, or $19.86 per share, on sales of $572.6 million for the three months ended June 30, for the bottom-line more than doubling and sales slightly declining compared […]
Bio-Rad shares steady on Street-topping Q1 earnings
Bio-Rad Laboratories (NYSE:BIO) shares are down slightly, but outpacing a general sell-off spurred by fears of a global trade war, after posting first quarter earnings that topped expectations on Wall Street. The Hercules, Calif.-based company posted profits of approximately $865.2 million, or $28.74 per share, on sales of approximately $554 million for the three months […]
Bio-Rad loses bid to re-hear $8m loss to former GC
The U.S. Court of Appeals for the Ninth Circuit late last month shot down a bid from Bio-Rad Laboratories(NYSE:BIO) to rehear a decision to affirm a loss to a former general counsel in a whistleblower retaliation suit, according to recently released court documents. Bio-Rad and its CEO had appealed a jury verdict in favor of […]
ReShape taps Allergan vet Bandy for CEO | Personnel Moves, April 3 2019
ReShape Lifesciences (NSDQ:RSLS) said last week that it named Allergan (NYSE: AGN) veteran Barton Bandy to replace Dan Gladney in the corner office, effective April 1. Gladney, who announced his retirement in January, is staying on as chairman. Bandy spent a decade at Inamed until its $3.2 billion purchase by Allergan in 2005. “I am […]
Ex-GC sues Bio-Rad, alleging retaliation for blowing the whistle
The former general counsel for Bio-Rad (NYSE:BIO) accused the company and CEO Norman Schwartz of firing him in retaliation for blowing the whistle on alleged violations of the Foreign Corrupt Practices Act in China. Sanford Wadler, who was general counsel and executive vice president when Bio-Rad sacked him in June 2013, alleged that he was fired right before […]
Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves
